Core Viewpoint - The company, Zhongji Changshou Science (00767), plans to acquire 25% of the issued share capital of Asia Comprehensive Cell Bank Limited for an initial consideration of HKD 300 million, with the option to issue up to HKD 300 million in non-redeemable convertible bonds to finance the acquisition [1] Group 1: Acquisition Details - The acquisition is set to take place on December 1, 2025, and will be financed through a combination of cash and convertible bonds [1] - Asia Comprehensive Cell Bank Limited specializes in high-end customized stem cell and IPSC storage services, catering primarily to high-net-worth individuals in Hong Kong and mainland China [1] Group 2: Business Operations - The target company operates under various trade names, including Weisman Academician International Advanced Medical Center and Asia International Medical Testing Center, employing a team of registered doctors and laboratory technicians [1] - The company provides preclinical immunotherapy services and testing, indicating a focus on advanced medical solutions [1] Group 3: Market Potential - The board believes that stem cell and IPSC storage services, along with cellular immunotherapy medical services, represent a high-growth potential business area [1] - Cellular immunotherapy services are experiencing exponential growth, driven by increasing consumer demand and investment interest in advanced skin regeneration, comprehensive vitality enhancement, and proactive health management strategies [1]

Core Viewpoint - The company, Zhongji Changshou Science (00767.HK), has announced a conditional agreement to acquire a 25% stake in the target company, Zonghe Zhaoxue Cell Bank Limited, for an initial consideration of HKD 300 million, which will be adjusted as specified in the agreement [1] Group 1: Acquisition Details - The acquisition will be financed through the issuance of non-redeemable convertible bonds to the seller, with a maximum amount of HKD 300 million, thus not impacting the company's cash flow [1] - The acquisition is expected to generate positive cash flow for the company in the upcoming fiscal year 2026, based on profit guarantees [1] Group 2: Target Company Overview - The target company operates a premium customized stem cell and IPSC storage center, providing testing and preclinical immunotherapy services to high-net-worth individuals, particularly in Hong Kong and China [1] - The target company conducts various medical tests, including patented high-standard early screening for circulating tumor cells and 21 other types of medical tests [1] - The target company is involved in research and development of novel cell-based preclinical immunotherapy, including natural killer cell therapies and umbilical cord-derived cell therapies [1] Group 3: Strategic Intent - The board is committed to improving the group's operational and financial conditions by actively seeking potential investment opportunities to diversify the existing business portfolio, expand revenue sources, and enhance shareholder value [2]

Core Viewpoint - Zhongji Changshou Science (00767) plans to acquire 25% of the issued share capital of Comprehensive Cell Bank Limited from China International Orthopedic Medical Group Co., Ltd. for an initial consideration of HKD 300 million, with the possibility of issuing redeemable convertible bonds up to HKD 300 million to finance this acquisition [1] Group 1: Acquisition Details - The acquisition is set to take place on December 1, 2025, with an initial payment of HKD 300 million [1] - The company will issue redeemable convertible bonds to cover the initial consideration, with a maximum amount of HKD 300 million [1] Group 2: Target Company Operations - The target company operates a boutique high-end customized stem cell and IPSC storage center, providing testing and preclinical immunotherapy services to clients, particularly high-net-worth individuals in Hong Kong and mainland China [1] - The target company operates under the trade names of Weisman Academician International Advanced Medical Center and Asia International Medical Testing Center, staffed by registered doctors and laboratory technicians [1] Group 3: Market Potential - The board believes that stem cell and IPSC storage services, along with cellular immunotherapy medical services, represent a new business area with significant growth potential [1] - Cellular immunotherapy services are experiencing exponential growth, driven by increased consumer demand and investment interest in advanced skin regeneration, comprehensive vitality enhancement, holistic health management, and proactive health management strategies [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本公告僅供參考，並不構成購入、購買或認購本公司任何證券之邀請或要約。 Zhong Ji Longevity Science Group Limited 中基長壽科學集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：767） 收購亞洲綜合細胞庫有限公司 25%已發行股本的 主要及關連交易 涉及根據特別授權 發行可換股票據 收購事項 董事會欣然宣佈，於二零二五年十二月一日（交易時段後），中國國際骨關節醫療 集團有限公司（「賣方」）（作為賣方）、本公司（作為買方）及閆立先生（「擔保人」） （作為擔保人）訂立買賣協議，據此，本公司有條件同意收購而賣方有條件同意出 售待售股份，佔亞洲綜合細胞庫有限公司（「目標公司」）已發行股本的25%，初始 代價為300,000,000港元（須按下文所述予以調整），並將根據特別授權向賣方發行 本金額最高達300,000,000港元的不可贖回可換股票據，藉此支付初始代價。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中基長壽科學集團有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00767 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 40,000,000,000 | HKD | | 0.01 | HKD | | 400,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 40,000,000,000 | HKD | | 0.01 | HKD | | 400,000,000 ...

Core Viewpoint - The company Zhongji Changshou Science (00767) announced significant changes in its board of directors, effective from November 27, 2025 [1] Group 1: Board Changes - Mr. Li Si has resigned as an independent non-executive director and will no longer serve as the chairman of the audit committee, as well as a member of the remuneration committee, nomination committee, risk management committee, and share award committee [1] - Ms. Wang Huijuan has been appointed as an independent non-executive director and will serve on the audit committee, remuneration committee, nomination committee, risk management committee, and share award committee [1] - Mr. Huang Jiang has been appointed as the chairman of the audit committee [1]

Core Points - Zhongji Changshou Science (00767) announced changes effective from November 27, 2025, regarding its board of directors [1] Group 1: Board Changes - Mr. Li Si has resigned as an independent non-executive director and will no longer serve as the chairman of the audit committee, as well as a member of the remuneration committee, nomination committee, risk management committee, and share award committee [1] - Ms. Wang Huijuan has been appointed as an independent non-executive director and will serve on the audit committee, remuneration committee, nomination committee, risk management committee, and share award committee [1] - Mr. Huang Jiang has been appointed as the chairman of the audit committee [1]

Group 1 - The company announced the resignation of Li Si as an independent non-executive director, effective from November 27, 2025 [1] - Wang Huijuan has been appointed as an independent non-executive director and a member of the audit committee, remuneration committee, nomination committee, risk management committee, and share award committee [1] - Huang Jiang has been appointed as the chairman of the audit committee [1]

獨立非執行董事 Zhong Ji Longevity Science Group Limited 中基長壽科學集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：767） 董事名單與其角色和職能 中基長壽科學集團有限公司董事會（「董事會」）成員載列如下： 執行董事 閆立先生 （主席及行政總裁） 李小雙先生 非執行董事 何亦武博士 呂長勝先生 黃江先生 （主席） 黃慈波教授 王慧娟女士 風險管理委員會 閆立先生 （主席） 黃江先生 黃慈波教授 王慧娟女士 黃江先生 黃慈波教授 王慧娟女士 董事會設有五個董事委員會，成員組合如下： 審核委員會 黃江先生 （主席） 黃慈波教授 王慧娟女士 – 1 – 提名委員會 閆立先生 （主席） 黃江先生 黃慈波教授 王慧娟女士 薪酬委員會 股份獎勵委員會 閆立先生 （主席） 黃江先生 黃慈波教授 王慧娟女士 香港，二零二五年十一月二十七日 本公告之中英文本如有任何歧義，概以英文本為準。 – 2 – ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Zhong Ji Longevity Science Group Limited 中基長壽科學集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：767） 獨立非執行董事變動； 董事委員會組成之變動；及 遵守上市規則第13.92條 董事會謹此宣佈，以下變動自二零二五年十一月二十七日起生效： 中基長壽科學集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）之董事（「董 事」）會（「董事會」）謹此宣佈以下變動，自二零二五年十一月二十七日起生效。 – 1 – 王女士已確認，彼(i)符合上市規則第3.13條所載的獨立標準；(ii)過往或現時並無於 本公司或其附屬公司的業務中擁有財務或其他權益，亦無與本公司任何核心關連人 士（定義見上市規則）有任何關連；及(iii)於彼獲委任時並無其他因素或會影響彼之 獨立性。 (1) 李思先生辭任獨立非執行董事，並不再擔任董事會審核委員會主席以及薪酬 委員會、提名委 ...